Figure 6. Panaxadiol suppressed tumor growth and reduced weights in xenograft pancreatic cancer models. (A) General changes of xenograft cancer models were by panaxadiol. (B) HE staining showed the pathological effect of panaxadiol between control and experimental groups, and immunohistochemical staining demonstrated the changes of Ki67 and Cleaved-caspase3 in tissues. (C–D) Panaxadiol significantly decreased the tumor weight and volume compared to control groups after being treated for 30 days. *P < 0.05. (E) The HE staining of liver and spleen. In vivo, panaxadiol possessed almost no cytotoxicity against normal tissues.